Allergan inc (AGN)
Income statement / TTM
Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10Dec'09Sep'09Jun'09Mar'09Sep'08Jun'08
Revenues:
Product net sales

7,126

6,896

6,634

6,384

6,197

5,985

5,811

5,660

5,549

5,281

5,238

5,212

5,144

5,254

5,135

4,966

4,819

4,736

4,671

4,558

4,447

4,323

4,351

0

0

0

Other revenues

111

115

119

102

102

102

94

98

97

92

87

79

72

71

70

69

99

98

95

92

56

54

57

0

0

0

Total revenues

7,237

7,011

6,753

6,486

6,300

6,088

5,905

5,758

5,646

5,373

5,325

5,292

5,216

5,326

5,205

5,035

4,919

4,834

4,767

4,651

4,503

4,377

4,408

0

0

0

Operating costs and expenses:
Cost of sales (excludes amortization of intangible assets)

842

837

823

800

795

774

764

761

751

719

724

724

718

749

739

735

722

723

736

743

750

761

768

0

0

0

Selling, general and administrative

2,837

2,807

2,682

2,573

2,519

2,346

2,279

2,233

2,193

2,114

2,130

2,133

2,158

2,222

2,201

2,133

2,017

1,987

1,967

1,910

1,921

1,864

1,873

0

0

0

Research and development

1,191

1,195

1,164

1,142

1,042

1,012

1,044

1,006

977

932

864

893

871

876

849

779

804

789

772

746

706

707

743

0

0

0

Amortization of intangible assets

112

113

112

113

116

111

105

99

90

57

66

74

86

128

127

133

138

141

146

144

146

149

149

0

0

0

Legal settlement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

Impairment of intangible assets and related costs

-

-

-

-

-

-

-

-

-

-

-

-

7

23

388

385

369

369

0

0

-

0

-

-

-

-

Restructuring charges

245

208

24

25

5

4

4

5

1

-3

-3

-4

-0

4

4

4

0

4

8

9

50

47

52

0

0

0

Operating income

2,009

1,837

1,934

1,820

1,809

1,816

1,683

1,630

1,611

1,568

1,555

1,478

1,374

1,322

287

255

258

208

1,135

1,096

928

848

821

0

0

0

Non-operating income (expense):
Interest income

7

7

7

7

6

7

7

7

6

6

6

5

6

8

8

8

7

5

5

5

7

12

21

0

0

0

Interest expense

69

72

73

73

75

71

68

65

63

65

64

62

71

82

88

86

78

72

69

74

76

76

79

0

0

0

Gain on investments, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

0

-

Unrealized (loss) gain on derivative instruments, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Other, net

41

23

-35

-8

-10

-16

-10

-16

-23

-30

4

-5

-0

0

-43

-23

-16

-7

-2

-35

-34

-30

-26

0

0

0

Total non-operating income (expense)

-20

-41

-101

-74

-78

-81

-71

-74

-80

-89

-54

-62

-65

-73

-122

-101

-87

-74

-42

-79

-79

-62

-77

0

0

0

Earnings from continuing operations before income taxes

1,989

1,796

1,833

1,745

1,730

1,734

1,612

1,555

1,531

1,479

1,501

1,416

1,309

1,249

164

154

170

133

1,093

1,017

848

785

743

0

0

0

Provision for income taxes

456

493

511

487

458

452

410

410

430

409

434

397

359

327

162

159

165

169

281

269

224

218

211

0

0

0

Earnings from continuing operations

1,532

1,302

1,322

1,258

1,272

1,282

1,202

1,145

1,100

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Discontinued Operations:
Earnings from discontinued operations, net of applicable income tax expense of $6.9 million and $0.5 million for the years ended December 31, 2013 and 2012, respectively

0

1

6

13

14

16

8

0

1

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on sale of discontinued operation, net of applicable income tax expense (benefit) of $1.3 million and $(110.3) million for the years ended December 31, 2014 and 2013, respectively

-3

-1

-39

-39

-297

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Expected loss on sale of discontinued operations, net of applicable income tax benefit of $21.1 million and $108.3 million for the three and nine months ended September 30, 2013, respectively

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Discontinued operations

-3

-0

-33

-25

-283

-280

-250

-258

1

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net earnings

1,528

1,302

1,289

1,232

988

1,001

951

886

1,102

1,057

1,057

1,009

938

921

1

-5

4

-35

812

747

623

567

531

0

0

0

Net earnings attributable to noncontrolling interest

4

2

2

2

3

5

5

5

3

2

2

3

3

3

4

3

4

5

4

3

2

1

2

0

0

0

Net earnings attributable to Allergan, Inc.

1,524

1,299

1,287

1,229

985

996

946

881

1,098

1,054

1,054

1,006

934

917

-2

-9

0

-41

808

744

621

565

529

0

0

0

Earnings per share attributable to Allergan, Inc. stockholders:
Basic earnings per share attributable to Allergan, Inc. stockholders:
Continuing operations (in dollars per share)

1.81

1.05

1.40

0.87

1.06

1.12

1.19

0.91

1.07

0.84

0.98

0.75

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Discontinued operations (in dollars per share)

0.00

0.00

0.00

-0.01

-0.01

-0.11

0.03

-0.87

0.00

-0.01

0.00

0.01

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net basic earnings per share attributable to Allergan, Inc. stockholders (in dollars per share)

1.81

1.05

1.40

0.86

1.05

1.01

1.22

0.04

1.07

0.83

0.98

0.76

0.92

0.82

0.81

0.52

0.87

-2.21

0.79

0.55

0.73

0.59

0.58

0.15

0.54

0.47

Diluted earnings per share attributable to Allergan, Inc. stockholders:
Continuing operations (in dollars per share)

1.78

1.03

1.37

0.85

1.04

1.10

1.17

0.89

1.05

0.82

0.96

0.74

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Discontinued operations (in dollars per share)

-0.02

0.00

0.00

0.00

-0.01

-0.10

0.02

-0.85

0.01

0.00

0.00

0.00

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net diluted earnings per share attributable to Allergan, Inc. stockholder (in dollars per share)

1.76

1.03

1.37

0.85

1.03

1.00

1.19

0.04

1.06

0.82

0.96

0.74

0.90

0.81

0.79

0.51

0.88

-2.21

0.78

0.55

0.72

0.58

0.58

0.15

0.54

0.47